SMYD3 polyclonal, anti-human, mouse
€388.00
In stock
SKU
BS8830
Background:
SET and MYND domain-containing 3 (SMYD3), a 428 amino acid protein, is a member of an RNA polymerase complex and plays a role in transcriptional regulation. SMYD3 methylates Lys 4 of histone H3, a specific tag for epigenetic transcriptional activation. The SMYD3 protein contains an N-terminal MYND-type zinc finger domain, followed by a SET domain, which shows methyltransferase activity. The presence of the heat-shock protein HSP 90α greatly enhances the methyltransferase activity of SMYD3. SMYD3 is expressed in testis and skeletal muscles and is overexpressed in a majority of colorectal carcinomas (CRCs), hepatocellular carcinomas (HCCs) and breast carcinomas (BCs). Inhibition of SMYD3 is a potential chemotherapeutic strategy.
Alternative Name:
Histone-lysine N-methyltransferase SMYD3, SET and MYND domain-containing protein 3, Zinc finger MYND domain-containing protein 1, SMYD3, ZMYND1, ZNFN3A1
Application Dilution: WB: 1:500~1:2000, IF: 1:50~1:200
Specificity: SMYD3 polyclonal antibody detects endogenous levels of SMYD3 protein.
Immunogen:
Recombinant full length Human SMYD3.
MW: ~ 49kDa
Swis Prot.: Q9H7B4
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
SET and MYND domain-containing 3 (SMYD3), a 428 amino acid protein, is a member of an RNA polymerase complex and plays a role in transcriptional regulation. SMYD3 methylates Lys 4 of histone H3, a specific tag for epigenetic transcriptional activation. The SMYD3 protein contains an N-terminal MYND-type zinc finger domain, followed by a SET domain, which shows methyltransferase activity. The presence of the heat-shock protein HSP 90α greatly enhances the methyltransferase activity of SMYD3. SMYD3 is expressed in testis and skeletal muscles and is overexpressed in a majority of colorectal carcinomas (CRCs), hepatocellular carcinomas (HCCs) and breast carcinomas (BCs). Inhibition of SMYD3 is a potential chemotherapeutic strategy.
Alternative Name:
Histone-lysine N-methyltransferase SMYD3, SET and MYND domain-containing protein 3, Zinc finger MYND domain-containing protein 1, SMYD3, ZMYND1, ZNFN3A1
Application Dilution: WB: 1:500~1:2000, IF: 1:50~1:200
Specificity: SMYD3 polyclonal antibody detects endogenous levels of SMYD3 protein.
Immunogen:
Recombinant full length Human SMYD3.
MW: ~ 49kDa
Swis Prot.: Q9H7B4
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review